As in many other tumor types, one of the main issues of PD-L1 expression assessing is the lack of reproducibility across tumor types: different clinical trials and anti-PD(L)1 drugs have led to different immunohistochemistry antibodies (22C3, SP142, 28-8...) and different thresholds for PD-L1+ tumors (>1%, 5%, 10%...) (90). Here, CD274 is linked to neoplasm.